Connect with us

Hi, what are you looking for?


Drug firms say stable regulation key to encouraging investment

THE pharmaceutical industry said further initiatives to streamline permit and approval processes and make regulation predictable will be key to inducing the industry to expand or attract investment.

Diana M. Edralin, Pharmaceutical and Healthcare Association of the Philippines (PHAP) said the industry is looking to the government to further improve the investment climate.

“One of the requests is some predictability in terms of the regulatory approval process. How do you (issue) licenses here? The tax incentivizes are only one aspect. Can I set up a site like in two weeks? Will I get my permit in two weeks’ time? The regulatory process is also critical,” Ms. Edralin said in a chance encounter with BusinessWorld.

Ms. Edralin said upgrades to the workforce are also needed ahead of any expansion or new investment.  

“When you talk about ease of doing business, it has to be expansive, going beyond the taxes. We need to prepare what the capabilities are needed so that when they invest in us, it is actually something that we can sustain,” Ms. Edralin said.

While tax incentives are “super helpful… how do we ensure that (when investors manufacture here at scale) that we have the manpower and technical expertise here?” she added.

According to Ms. Edralin, the Philippines has improved the process of drug approvals with the reliance pathway used by the Food and Drug Administration (FDA), which takes into account drug approvals by other countries.

“The average (time) used to be two to three years; that’s long. But now, the FDA has made very significant progress. The FDA learned a lot during the pandemic with the approval of the vaccines. We managed to get a drug approval in 48 days with the reliance pathway,” Ms. Edralin said.

Ms. Edralin said that the group is not expecting logistics issues to disrupt the medicine supply this year.

“I don’t think we are anticipating any for this year. But as a country, we need to be prepared in terms of what did we learn from the pandemic,” Ms. Edralin said.

Ms. Edralin said PHAP members have been monitoring the Russia-Ukraine war for its potential to affect the supply of pharmaceuticals.

“All of our companies have a very strong global supply chain team… With these global organizations, we have the ability to anticipate and we’re doing our best,” Ms. Edralin said.

“Should (supply issues) happen, we will inform ahead of time but right now that has not happened because we heavily invest in ensuring continuity of supply of life-saving medications,” she added. — Revin Mikhael D. Ochave

Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

You May Also Like

World News

Toronto’s school board has become the first in Canada to recognize that caste discrimination exists in the city’s schools and has asked a provincial...


A PROPOSAL to reduce tariffs to zero for imports of natural gypsum will stimulate domestic production of gypsum board, a construction material used in...


Tomorrow is Ash Wednesday. For Catholics around the world, it is the beginning of Lent, a period for reflection and contemplation. Speaking of reflection,...


THE Bureau of Internal Revenue (BIR) is studying the establishment of an international tax division specializing in deterring transfer pricing abuses. “We are trying...

Dislaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2023 All Rights Reserved. Spirit